Psyence Biomedical Faces Nasdaq Delisting Risk

TL;DR

Nasdaq warning for Psyence Biomedical - need to boost share price by Dec or get booted!

AI Summary

On June 27, 2024, Psyence Biomedical Ltd. received a notification letter from Nasdaq regarding its failure to meet the minimum bid price requirement, with a compliance period until December 23, 2024. The company is exploring strategic options to regain compliance.

Why It Matters

Failure to regain compliance with Nasdaq's minimum bid price could lead to the delisting of Psyence Biomedical's shares, impacting liquidity and investor confidence.

Risk Assessment

Risk Level: medium — The company is at risk of delisting from Nasdaq if it cannot meet the minimum bid price requirement by the specified deadline.

Key Numbers

• $1.00 — Minimum Bid Price (The minimum bid price requirement set by Nasdaq that Psyence Biomedical must meet.)

Key Players & Entities

• Psyence Biomedical Ltd. (company) — The company that received the notification
• Nasdaq Stock Market (company) — The stock exchange that issued the notification
• June 27, 2024 (date) — Date the notification letter was received
• December 23, 2024 (date) — Deadline for compliance with Nasdaq's minimum bid price requirement

FAQ

Key Financial Figures

• $1.00 — s closing bid price per share was below $1.00 for a period of 30 consecutive business
• $5,000 — application and submit a non-refundable $5,000 application fee. The Company will be re

Filing Documents

• tm2418761d1_6k.htm (6-K) — 12KB
• tm2418761d1_ex99-1.htm (EX-99.1) — 11KB
• 0001104659-24-077897.txt ( ) — 25KB

From the Filing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2024 Commission File Number: 001-41937 Psyence Biomedical Ltd. (Translation of registrant's name into English) 121 Richmond Street West Penthouse Suite 1300 Toronto, Ontario M5H 2K1 (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F x Form 40-F ¨ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨ On June 27, 2024, Psyence Biomedical Ltd. (the "Company") received a notification letter from the Listings Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that the Company's closing bid price per share was below $1.00 for a period of 30 consecutive business days and that the Company did not meet the minimum bid price requirement set forth in Nasdaq Listing Rule 5450(a)(1) (the "Minimum Bid Price Rule"). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), Nasdaq provided the Company with 180 calendar days, or until December 24, 2024 (the "Compliance Period"), to regain compliance with the Minimum Bid Price Rule. If at any time during the Compliance Period, the closing bid price per share of the Company's common shares is at least $1.00 for a minimum of ten (10) consecutive business days, Nasdaq will provide the Company a written confirmation of compliance with the Minimum Bid Price Rule and the matter will be closed. In the event the Company does not regain compliance with the Minimum Bid Price Rule by December 24, 2024, the Company may be eligible for additional time. To qualify, the Company must submit, no later than December 24, 2024, an on-line transfer application and submit a non-refundable $5,000 application fee. The Company will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards, with the exception of the bid price requirement, and will need to provide written notice of its intention to cure the deficiency during the second compliance period, including by effecting a reverse stock split, if necessary. As part of its review process, the Staff will make a determination of whether the Staff believes the Company will be able to cure this deficiency. If the Staff concludes that the Company will not be able to cure the deficiency, or if the Company determines not to submit a transfer application or make the required representation, Nasdaq will provide notice that the Company's securities will be subject to delisting. If the Company chooses to implement a reverse stock split, it must complete the split no later than ten (10) business days prior to December 24, 2024, or the expiration of the second compliance period if granted. The Nasdaq notification letter does not result in the immediate delisting of the Company's common shares, and the common shares will continue to trade uninterrupted under the symbol "PBM." The Company intends to consider its available options to resolve the Company's noncompliance with the Minimum Bid Price Rule. A copy of the press release is furnished hereto as Exhibit 99.1. Exhibits Exhibit Number Description 99.1 Press Release, dated July 3, 2024. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Dated: July 3, 2024 Psyence Biomedical Ltd. By: /s/ Dr. Neil Maresky Name: Dr. Neil Maresky Title: Chief Executive Officer and Director

View Full Filing

View this 6-K filing on SEC EDGAR